Abstract
The paper presents the results of a study of a low-dose drug for continuous HRT - Femoston 1/5. The drug quite effectively eliminates (reduces) psychoemotional and vegetative-vascular symptoms of peri- and postmenopause, eases the course of hypertension, does not affect body weight gain, actually does not cause breakthrough bleeding, growth of myomatous nodes, does not affect the size of the uterus and the thickness of the endometrium (within a year reception). Taking the drug is accompanied by positive dynamics of the level of glycemia, high and low density lipoproteins, the degree of aggregation and intravascular activation of platelets, which improves the state of peripheral blood flow.
 The presented data allow us to recommend Femoston 1/5 as a means of HRT for postmenopausal and perimenopausal patients with concomitant uterine myoma and endometriosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
